.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,149,935

« Back to Dashboard

Details for Patent: 6,149,935

Title: Solid matrix system for transdermal drug delivery
Abstract:A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix, formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred embodiments the matrix is used to administer steroids, in particular estradiol. Water-soluble polymers may be added as well.
Inventor(s): Chiang; Chia-Ming (Foster City, CA), Tenzel; Renee Ann (Mountain View, CA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Filing Date:Aug 16, 1999
Application Number:09/375,837
Claims:1. A method for making an estrogen-containing matrix for use in a transdermal drug delivery device for administering at least one estrogen to an area of skin or mucosa, comprising the estrogen dispersed in a body of a pressure sensitive adhesive, the method comprising:

a) incorporating an estrogen into a pressure sensitive adhesive material and a volatile solvent, to form a homogeneous solution or slurry;

b) casting the homogeneous solution or slurry; and

c) evaporating the volatile solvent from the homogeneous solution or slurry to form a solid matrix,

wherein the pressure sensitive adhesive comprises an acrylate copolymer and polyvinylpyrrolidone, said matrix being essentially free of a skin permeation enhancer.

2. The method of claim 1, wherein incorporating comprises dissolving the estrogen in the solution or slurry of the pressure sensitive adhesive material and the volatile solvent.

3. The method of claim 1, wherein incorporating comprises finely dispersing the estrogen in the homogeneous solution or slurry of the pressure sensitive adhesive material and the volatile solvent.

4. The method of claim 1, wherein incorporating comprises mixing the estrogen with the volatile solvent prior to adding the pressure sensitive adhesive material.

5. The method of claim 1, wherein the solid matrix comprises a layer between 10 micrometers and about 250 micrometers in thickness.

6. The method of claim 5, wherein the solid matrix comprises a layer between 15 micrometers and 100 micrometers in thickness.

7. The method of claim 1, wherein evaporating comprises a technique selected from the group consisting of heat, air flow, vacuum, and combinations thereof.

8. The method of claim 7, wherein evaporating is carried out between room temperature and about 100.degree. C.

9. The method of claim 7, wherein evaporating is carried out until less than 5 wt % of the volatile solvent remains in the matrix.

10. The method of claim 9, wherein evaporating is carried out until less than 1 wt % of the volatile solvent remains in the matrix.

11. The method of claim 1, further comprising (d) laminating the solid matrix onto a release liner.

12. The method of claim 1, wherein the pressure sensitive adhesive material comprises a copolymer of 2-ethylhexyl acrylate and at least one copolymer selected from the group consisting of methyl acrylate, acrylic acid, and vinyl acetate.

13. The method of claim 12, wherein the pressure sensitive adhesive material comprises approximately 70 wt % 2-ethylhexyl acrylate and approximately 30 wt % vinyl acetate.

14. The method of claim 12, wherein the pressure sensitive adhesive material comprises approximately 72 wt % 2-ethylhexyl acrylate and approximately 28 wt % vinyl acetate.

15. The method of claim 12, wherein the pressure sensitive adhesive material comprises approximately 85 wt % 2-ethylhexyl acrylate, 10 wt % methyl acrylate, 3 wt % acrylic acid, and 2 wt % vinyl acetate.

16. The method of claim 1, wherein the estrogen is selected from the group consisting of estradiol, estradiol valerate, estradiol cyprionate, estradiol decanoate, estradiol acetate, and ethinyl estradiol.

17. The method of claim 1, wherein the homogeneous solution or slurry further comprises a progestogen.

18. The method of claim 17, wherein the progestogen is selected from the group consisting of norethindrone, norethindrone acetate, desogestrel, 3-keto desogestrel, gestadene, and levonorgestrel.

19. The method of claim 1, wherein the pressure sensitive adhesive material further comprises a water-soluble polymer.

20. The method of claim 19, wherein the water soluble polymer comprises polyvinylpyrrolidone.

21. The method of claim 19, wherein the water soluble polymer comprises polyvinylalcohol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc